Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes

Journal of Investigative Medicine

Volumn 60, Issue 7, 2012, Pages 1059-1063

  Lingvay, Ildiko ^a,b   Roe, Erin D ^a,b   Duong, Jonathan ^b   Leonard, David ^a   Szczepaniak, Lidia S ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Hepatic steatosis; Insulin; NAFLD; Triglyceride; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; LIPID; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEPATIC TRIGLYCERIDE CONTENT; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID STORAGE; LIVER BIOPSY; LIVER FUNCTION TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPEN STUDY;

ADMINISTRATION, ORAL; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TRIGLYCERIDES; YOUNG ADULT;

EID: 85006136707     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3182621c5f     Document Type: Article

References (32)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387-1395.
2. Kelley DE, McKolanis TM, Hegazi RA, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab. 2003;285(4): E906YE916.
3. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89(1):200-206.
4. Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003;52(6): 1364-1370.
5. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 30 2006;355(22):2297-2307.
6. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39(1):188-196.
7. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6(9): 998-1003.
8. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358(9285):893-894.
9. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100(5): 1082-1090.
10. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004;19(5):537-544.
11. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53(8): 2169-2176.
12. Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;20(1):23-28.
13. Anderwald C, Bernroider E, Krssak M, et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes. 2002;51(10):3025-3032.
14. Zib I, Jacob AN, Lingvay I, et al. Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. J Investig Med. 2007;55(5):230-236.
15. Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications. 2007;21(3):137-142.
16. Garber AJ. Benefits of combination therapy of insulin and oral hypoglycemic agents. Arch Intern Med. 2003;163(15): 1781-1782.
17. Lingvay I, Legendre JL, Kaloyanova PF, et al. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care. 2009;32(10):1789-1795.
18. Boesch C, Slotboom J, Hoppeler H, et al. In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. Magn Reson Med. 1997;37(4):484-493.
19. Schick F, Eismann B, Jung WI, et al. Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue. Magn Reson Med. 1993;29(2): 158-167.
20. Szczepaniak LS, Dobbins RL, Metzger GJ, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003;49(3):417-423.
21. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol. 1999;276(5 Pt 1):E977-989.
22. McGavock JM, Victor RG, Unger RH, et al. Adiposity of the heart, revisited. Ann Intern Med. 2006;144(7):517-524.
23. McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116(10):1170-1175.
24. Reingold JS, McGavock JM, Kaka S, et al. Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. Am J Physiol Endocrinol Metab. 2005;289(5):E935YE939.
25. Lingvay I, Raskin P, Szczepaniak LS. The fatty hearts of patients with diabetes. Nat Rev Cardiol. 2009;6(4):268-269.
26. Lingvay I, Esser V, Legendre JL, et al. Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab. 2009;94(10): 4070-4076.
27. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288(2):E462YE468.
28. Szczepaniak LS, Dobbins RL, Stein DT, et al. Bulk magnetic susceptibility effects on the assessment of intra- and extramyocellular lipids in vivo. Magn Reson Med. 2002;47(3):607-610.
29. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-1321.
30. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7):1898-1906.
31. Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol. 1998;11(6):560-565.
32. Juurinen L, Tiikkainen M, Hakkinen AM, et al. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292(3): E829YE835.